Jean-Noël Bidard

Ciguatoxin and brevetoxins share a common receptor site on the neuronal voltage-dependent Na+ channel.

Binding studies indicate that ciguatoxin and brevetoxin allosterically enhance in a very similar way the binding of [3H]batrachotoxinin A 20‐α‐benzoate to the neuronal Na+ channel protein. Moreovr ciguatoxin competitively inhibits the binding of [3H]brevetoxin‐3 to rat brain membranes. The affinity of ciguatoxin for the Na+ channel is at least 20–50‐times higher than that of brevetoxin. These results indicate that ciguatoxin and brevetoxins act at the same binding site on the sodium channel.

BIOCHEMICAL PROPERTIES OF THE BRAIN PHENCYCLIDINE RECEPTOR

This paper gives a detailed account of techniques which can be used to measure [3H]phencyclidine binding to its receptor. The main properties of the binding component are the following: (i) It is rapidly heat-inactivated at temperatures over 50 degrees C. (ii) It is destroyed by proteases like trypsin, pronase or papain suggesting that it is of a protein nature. The receptor structure is resistant to chymotrypsin. (iii) A good correlation was found between the pharmacological activity of 30 different analogs as measured by the rotarod assay and the affinity of these different molecules for the phencyclidine receptor. (iv) Monovalent and divalent cations antagonize [3H]phencyclidine binding to its receptor. The dissociation constant is 15 mM, the same for Na+, Li+, K+, cholinium or Tris. Na+ (and other monovalent cations) and phencyclidines bind to distinct sites. The saturation of the Na+ site by Na+ modulates the affinity of phencyclidine for its receptor. Divalent cations antagonize [3H]phencyclidine binding in the absence of Na+. This antagonism is of the non-competitive type. (v) [3H]phencyclidine binding is also antagonized by histrionicotoxin and by local anaesthetics.

Two potent central convulsant peptides, a bee venom toxin, the MCD peptide, and a snake venom toxin, dendrotoxin I, known to block K+ channels, have interacting receptor sites

Both the bee venom toxin, mast cell degranulating peptide (MCD peptide) and the mamba toxin dendrotoxin I are potent central convulsants. The two specific receptor sites for these two types of polypeptide toxins are in allosteric interaction in brain membranes. Occupation of the dendrotoxin I binding site (KI = 0.4 nM) prevents binding of the 125I-MCD peptide to its own receptor (KI = 0.23 nM). This inhibition is of the non-competitive type. Autoradiography has shown that a high enough dendrotoxin I concentration (30 nM) prevented binding of 125I MCD peptide to all brain structures where specific receptors had been identified. A lower concentration of the mamba toxin led to a nearly selective inhibition of MCD peptide binding to the hippocampal region which is responsible for the convulsant properties of the 2 types of polypeptide toxins.

Purification and pharmacological characterization of peptide toxins from the black mamba (Dendroaspis polylepis) venom

This paper reports the purification of 28 different peptides from the venom of the snake Dendroaspis polylepis. These peptides represent 99% of the total peptide fraction in the venom. The 14 most cationic peptides form a structurally and functionally homogeneous group of analogs of the most abundant dendrotoxin toxin I (DTXI). They recognize antibodies raised against DTXI as well as brain membrane binding sites corresponding to K+ channels that are sensitive to DTXI and the bee venom peptide MCD. Similarly to DTXI these 14 peptides induce convulsions after intracerebroventricular injections in mice and induce GABA release from synaptosomes. However, members in this iso-DTXI family differ widely in their affinity for the DTXI/MCD receptors and in their contractility promoting action on intestinal smooth muscle. The 14 other less cationic peptides do not interact with the DTXI receptor or with DTXI antibodies and they do not evoke GABA release. Their targets seem to be essentially of a peripheral nature. Half of them contract guinea pig ileum. In this group of toxins there might be new tools to study membrane excitability.

Charybdotoxin blocks dendrotoxin-sensitive voltage-activated K+ channels.

Charybdotoxin, a short scorpion venom neurotoxin, which was thought to be specific for the blockade of Ca2+‐activated K+ channels also blocks a class of voltage‐sensitive K+ channels that are known to be the target of other peptide neurotoxins from snake and bee venoms such as dendrotoxin and MCD peptide. Charybdotoxin also inhibits 125‐dendrotoxin and 125I‐MCD peptide binding to their receptors. All these effects are observed with an IC50 of about 30 nM.

Analogies and differences in the mode of action and properties of binding sites (localization and mutual interactions) of two K+ channel toxins, MCD peptide and dendrotoxin I

Both the bee venom toxin, mast cell degranulating (MCD) peptide, and the snake toxin, dendrotoxin 1 (DTX1) induce epileptiform activity and paroxystic seizures after intracerebroventricular (i.c.v.) injection to rats. Although many of the properties of the two toxins, which are blockers of the same K+ channel, appear to be very similar, a number of differences have been found. (1) Induced seizures have an hippocampal origin for MCD and two different origins, situated in the cortex and in the limbic system, for DTX1. (2) A first i.c.v. administration of DTXI desensitizes against a second ipsilateral injection of the same peptide as we had previously observed for MCD. However no cross-desensitization was observed between the two different toxins. (3) The number of high affinity (Kd = 41 pM) binding sites for 125I-DTXI in synaptic membranes is about 5 times higher than the number of high affinity (Kd = 158 pM) binding sites for 125I-MCD. (4) Autoradiographic analysis of the distribution of high affinity 125I-DTX1 binding sites has been compared to our previous analysis of high affinity 125I-MCD binding sites. High levels of high affinity binding sites for both toxins seem to be localized in synapse-rich areas. However high affinity binding sites for the two toxins are not always co-localized. Analysis of the mutual interactions between DTXI and MCD binding sites has revealed the presence of classes of low affinity binding sites for MCD. In most areas of the brain, a large proportion of high affinity binding sites for DTXI is allosterically related to low affinity binding for MCD.

Subtypes of K+ channels differentiated by the effect of K+ channel openers upon K+ channel blocker-induced seizures

Intracerebroventricular injection of mast-cell degranulating peptide (MCD), dendrotoxin I (DTXI) and 4-aminopyridine (4-AP), 3 blockers of a subclass of K+ channel, produces seizures and convulsions. Three different K+ channel openers are potent blockers of MCD-induced hyperexicitatory effects when they are administered preventively but they are unable to inhibit the epileptogenic effects induced by DTXI and 4-AP which were thought to block the same K+ channel which is blocked by MCD.

The brain response to the bee venom peptide MCD. Activation and desentization of a hippocampal target

The mast cell-degranulating peptide (MCD) isolated from bee venom has been found previously to have receptor sites in rat brain. Behavioral and electrocorticographic responses following intracerebroventricular injections of various doses of MCD have been analyzed. MCD produced a quasi-permanent hippocampal theta rhythm in the motionless animal alternating with epileptiform spike waves and paroxystic seizures. At a dose of 70 pmol seizures occurred for half of the treated rats. At a dose of 100 pmol generalized paroxystic crises were observed for all the rats. These effects were not antagonized by naloxone, morphine, diazepam and progabide. Rats recovered 24 h after a 100 pmol injection of MCD. A second ipsilateral injection to these rats showed the occurrence of a desensitization phenomenon. Desensitization was not observed when the second injection was contralateral. These physiological responses were studied in relation with a biochemical approach on membrane sites of action of MCD using [125I]MCD and their behavior in the desensitization process. The target of [125I]MCD is the ipsilateral hippocampus. Recovery from MCD effects was not due to MCD degradation. Desensitization was not due to down-regulation of the MCD receptor level.

High affinity receptors for the bee venom MCD peptide. Quantitative autoradiographic localization at different stages of brain development and relationship with MCD neurotoxicity

High densities of MCD receptors were found in the stratum radiatum of Ammons horn, the neocortex, the molecular layer of the cerebellum, colliculi and pons. Conversely areas such as the stratum lacunosum moleculare of Ammons horn contained only low levels of MCD binding sites. The density of MCD receptors is low during the perinatal period and increases rapidly by postnatal day 10 with a decrease of the receptor affinity for MCD. The adult distribution of MCD receptors was reached at postnatal day 30. Increases in density of MCD receptors are discussed in relation with increased neurotoxicity of MCD during brain development. Effects of MCD during the perinatal period are very weak. However, the threshold MCD dose to induce seizures drastically decreased after the first postnatal week. The efficient dose corresponding to adult stage is reached after postnatal day 40.

Ca2 channel blockers prevent seizures induced by a class of K+ channel inhibitors

Intracerebroventricular injection into rats of mast-cell degranulating peptide (MCD), dendrotoxin I (DTXI) and 4-aminopyridine (4-AP), three blockers of a subclass of K+ channels, elicited epileptiform wave bursts and convulsions. Three different types of L-type Ca2+ channel inhibitors (+)PN 200-110, a 1,4-dihydropyridine, (-)D888, a phenylalkylamine, and fluspirilene, a diphenylbutylpiperidine, were potent blockers of the convulsant-induced hyperexcitatory effects when they were administered preventively. D-AP5, a N-methyl-D-aspartate antagonist, was active on the 4-AP-induced seizures but was without effect on the MCD- and dendrotoxin-induced seizures.